Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
← CataloguePlate 42 of 81
42Plate 42Reviewed 2026-04-27

Livagen

Khavinson Bioregulator

also known as KEDA, Lys-Glu-Asp-Ala

Synthetic tetrapeptide (Lys-Glu-Asp-Ala) developed in the Khavinson bioregulator tradition for liver tissue support. Animal models demonstrate hepatoprotective effects in fibrosis, acute and chronic hepatitis, with tissue-specific stimulation of hepatocyte protein synthesis and age-dependent normalization of digestive enzyme activity. Resists hydrolysis by intestinal peptidases; oral administration viable.

§ I

At a glance

Dipeptidase inhibition
50%
Routes tested
Oral / SQ
Target tissue
Liver
Route

Oral or SQ · Tissue-specific to liver

§ II

Mechanism

Edit ↗

Primary target — Hepatocyte protein synthesis machinery [brodski-2001].

Pathway — Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalization [brodski-2001][khavinson-2001].

Downstream effect — Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes.

Origin — Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil).

§ III

Dosage

Protocols described in the cited literature; not medical advice.

Edit ↗
ParameterValue
Animal dose (oral)Not specified in abstracts; 2-week administration protocol [timofeeva-2005]Per os administration in rats.
Duration (experimental)2 weeks (enzyme study); up to 24 months (cell culture) [timofeeva-2005][brodski-2001]
RouteOral or subcutaneousResists peptidase hydrolysis, enabling oral bioavailability. [timofeeva-2005]
Evidence basisAnimal models (rats, 1–24 months age); in vitro hepatocyte culture [timofeeva-2005][brodski-2001][khavinson-2002]
Human dataNone in provided literature
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
mg
mL
mcg
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to Livagen's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
0.100mL
10.0 units on a U-100 insulin syringe
Concentration
2500
mcg per mL
Doses per vial
20
at this dose

Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.

§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Edit ↗
Reported adverse effectsmild
None documented in animal studies
Human safety datamild
No human trials in provided literature
Peptide hydrolysismild
Weakly hydrolyzed; minimal breakdown by intestinal enzymes [timofeeva-2005]
§ VI

Administration

Edit ↗
  1. 01
    Route selection

    Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments. [timofeeva-2005][khavinson-2001]

  2. 02
    Timing

    No specific timing documented. Two-week protocols used in animal models with daily administration. [timofeeva-2005]

  3. 03
    Age-dependent response

    Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings. [timofeeva-2005]

Appendix

Sources

63%

of 32 rendered claims carry a resolvable citation.

  1. [brodski-2001]
    Brodskiĭ 2001[Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen].
    journal, 2001
  2. [khavinson-2001]
    Khavinson 2001Tissue-specific effects of peptides.
    journal, 2001
  3. [khavinson-2002]
    Khavinson 2002Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway.
    journal, 2002
  4. [kuznik-2020]
    Kuznik 2020[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.].
    journal, 2020
  5. [timofeeva-2005]
    Timofeeva 2005[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].
    journal, 2005
Plate composed 2026-04-27 · maturity human-reviewed · schema v1 · Contributors: peptidesdb-core · 12 fields uncited — open contributions